Belzutifan
Back to searchMolecule Structure
Scientific Name
Belzutifan
Description of the Drug
Belzutifan is an inhibitor of hypoxia-inducible factor 2α used as an antineoplastic in the treatment of certain cancers associated with von Hippel-Lindau (VHL) disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB15463
http://www.drugbank.ca/drugs/DB15463
Brand Name(s)
Welireg
Company Owner(s)
Merck Sharp And Dohme Corp A Sub Of Merck And Co Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Endothelial PAS domain-containing protein 1 | SINGLE PROTEIN | INHIBITOR | CHEMBL1744522 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL16560918 |
| PharmGKB | PA166268761 |
| Human Metabolome Database | HMDB0304835 |
| DrugBank | DB15463 |
| PubChem | 117947097 |
| PDBe | 72Q |
| BindingDB | 373040 |
| ChemicalBook | CB75488378 |
| Guide to Pharmacology | 11251 |
| ZINC | ZINC000584905085 |
